On January 7, 2020, Ms. Ling Fan, Deputy Director of China National Center for Biotechnology Development, and her delegation visited Alphamab Oncology. Dr. Ting Xu, Founder, Chairman and CEO of Alphamab Oncology, extended a warm welcome to Deputy Director Ling Fan and her delegation.
Alphamab Oncology is dedicated to addressing the unmet medical needs in the field of oncology and has achieved exciting R&D progress, and known as a leading biopharma with one of the strongest in-house R&D capabilities in China. With multiple in-house proprietary platforms such as sdAb, CRIB and CRAM, Alphamab Oncology has unique innovation advantages in the field of bispecific antibody drug development. The Company’s four drug candidates have advanced into Phase I – III clinical development phases in China, US and Japan. Meanwhile, we have established our new state-of-the-art manufacturing facility with advanced large-scale capabilities (2X2000 Liter) in Suzhou Industrial Park in compliance with China NMPA, US FDA and EU EMA cGMP standards, which enables the company to have sufficient support for its global clinical trials.
During the forty-minute visit, Deputy Director Ling Fan actively discussed with Dr. Xu and asked several questions “What is the biggest advantage of Alphamab Oncology’s technology platform?” “Why did you come back to start a business in China?” Dr. Xu answered these questions during this visit.
After learning that Alphamab Oncology has completed two consecutive rounds of Financing within half a year, and successfully listed in Hong Kong within about half year after the completion of Series B Financing, Deputy Director Ling Fan was impressed and commented that this is strong proof of the company's value and future development potential!
During the visit, Deputy Director Ling Fan spoke highly of Dr. Ting Xu's scientific research experience and the decision to start a business in China. She also suggested, “Dr. Xu has done impressive work in research and development since returning to China and building a talented team. With the company's IPO and expansion, I believe that the company will grow rapidly and make greater contributions to the development of China's biopharma industry.
Accompanying members of this visit include Junxiang Yin, Researcher of the Medicine and Public Health Division of China National Center for Biotechnology Development, and Yiping Zhang, Intern Researcher from Planning and Coordination Division.
About Alphamab Oncology
Alphamab Oncology is a biopharmaceutical company focusing on the research and development, manufacturing and commercialization of biologics for oncology. In December 12, 2019, the Company was listed in the mainboard of Hong Kong Stock Exchange with stock code 9966.
Alphamab has fully integrated proprietary biologics platform in bi-specifics and protein engineering. Its highly differentiated in-house pipeline consists of eight anti-cancer drug candidates, four of which have advanced into Phase I – III clinical development phases in China, US and Japan.
The Company also has proprietary CRIB and CRAM platforms for bi-specifics and antibody mixtures, and state-of-the-art manufacturing capability designed and built to meet NMPA and EU/FDA’s cGMP standards.
With multiple in-house proprietary platforms for innovative biopharmaceuticals, Alphamab Oncology has built a robust pipeline in oncology/immunology to benefit cancer patients around the world.
Visit http://www.alphamabonc.com for more information..
